

SWOG S2013 I-CHECKIT Tweets

Week One: Patient-Focused Tweets (one per day, Monday through Friday)

#Immunotherapy drugs may help a person's immune system fight #cancer. But people can have side effects from them. #ClinicalTrial S2013 wants to better predict who is likely to have serious side effects. To learn more, call 1-800-4-Cancer. Ask about S2013. @SWOG @theNCI #LCSM

New @SWOG #ICHECKIT #cancer trial S2013 asks: Can we predict which cancer patients are most at risk for serious side effects from widely used immune therapy drugs? To learn more, visit SWOG.org/S2013 or call 1-800-4-Cancer and ask about S2013. @theNCI #CRCSM #ImmunoOnc

Immune therapy drugs are used to treat some #cancers, such as #melanoma, #kidneycancer, & #lungcancer. Trial S2013 #ICHECKIT tracks side effects from these drugs. To learn more, call 1-800-4-Cancer. Ask about S2013. Or visit SWOG.org/S2013. @theNCI @SWOG

#ClinicalTrial S2013 #ICHECKIT follows patients taking #immunotherapy drugs for #cancer, to learn who is at risk for serious side effects. To learn more about S2013, visit SWOG.org/S2013. Or call 1-800-4-Cancer and ask about S2013. @SWOG @theNCI @Alliance_org #GynCSM

Many people with #cancer are treated with drugs called immune checkpoint inhibitors. #ClinicalTrial S2013 #ICHECKIT may help us predict who is at risk for side effects from these drugs. Learn more: SWOG.org/S2013. Or call 1-800-4-CANCER. Ask about S2013. @SWOG @theNCI

Week Two: Provider-Focused Tweets (one per day, Monday through Friday)

PI @kgunturuMD of @LaheyHospital co-leads @SWOG's new S2013 #ICHECKIT cancer trial. It's developing a model to predict which patients are most likely to have serious adverse events from immune checkpoint inhibitors. SWOG.org/clinical-trials/S2013. @theNCI #ImmunoOnc

.@SWOG S2013 #ICHECKIT will validate a risk prediction model for grade-3+ immune-related adverse events (#irAEs) from #immunotherapy in solid tumors. Co-led by @DrDawnHershman of @NYPhospital and @ColumbiaMed. @theNCI #NCORP SWOG.org/clinical-trials/S2013 #ImmunoOnc

S2013 #ICHECKIT is a @SWOG observational study of #immunecheckpoint inhibitor toxicity. It requires lab tests and patient-reported outcome questionnaires at five time points. Patients follow standard of care treatment for their cancer. SWOG.org/clinical-trials/S2013 @theNCI

Immune checkpoint inhibitors are used to treat more than a dozen cancers. But side effects can range from fatigue & diarrhea to colon or liver damage. @SWOG's S2013 #ICHECKIT is developing a model for personalized ICI risk/benefit assessment. SWOG.org/clinical-trials/S2013 #ImmunoOnc

New @SWOG S2013 Immune CHECKpoint Inhibitor Toxicity (#ICHECKIT) study complements @Alliance_org trial A151804. Co-enrollment allowed. Patients on #immunotherapy may be eligible for S2013. Those with grade 3-5 #irAEs may be eligible for A151804. SWOG.org/clinical-trials/S2013

S2013 Twitter Graphics

Graphics for patient-focused tweets:

NEW CANCER TRIAL

Patients taking immune checkpoint inhibitors for solid tumors may be eligible for this trial.

Call 1-800-4-CANCER
Ask about S2013

SWOG | CANCER RESEARCH NETWORK

NEW CANCER TRIAL

Trial S2013 follows patients getting cancer immunotherapy to predict who is at risk for side effects.

Call 1-800-4-CANCER
Ask about S2013

SWOG | CANCER RESEARCH NETWORK

NEW CANCER TRIAL

Will your cancer be treated with immune therapy?

Call 1-800-4-CANCER
Ask about S2013

SWOG | CANCER RESEARCH NETWORK

NEW CANCER TRIAL

Will your cancer be treated with immune therapy?

Call 1-800-4-CANCER
Ask about S2013

SWOG | CANCER RESEARCH NETWORK

Graphics for provider-focused tweets:

NEW CANCER TRIAL: S2013 I-CHECKIT

Now enrolling: Can we predict who is at greatest risk for serious side effects from immune checkpoint inhibitors?

[Learn more at SWOG.org](https://www.swog.org)



Krishna Gunturu, MD | S2013 Co-Lead

NEW CANCER TRIAL: S2013 I-CHECKIT

S2013 I-CHECKIT is developing a risk prediction model for grade-3+ immune-related adverse events from immune checkpoint inhibitors.

[Learn more at SWOG.org](https://www.swog.org)



Krishna Gunturu, MD | S2013 Co-Lead

NEW CANCER TRIAL: S2013 I-CHECKIT

Now enrolling: Can we predict who is at greatest risk for serious side effects from immune checkpoint inhibitors?

[Learn more at SWOG.org](https://www.swog.org)



Dawn Hershman, MD, MS | S2013 Co-Lead

NEW CANCER TRIAL: S2013 I-CHECKIT

S2013 I-CHECKIT is developing a risk prediction model for grade-3+ immune-related adverse events from immune checkpoint inhibitors.

[Learn more at SWOG.org](https://www.swog.org)



Dawn Hershman, MD, MS | S2013 Co-Lead